ReviewAnnual review of pathology2013
Pathological and molecular advances in pediatric low-grade astrocytoma.
Review in Annual review of pathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 76 citations in OpenAlex.
- Single agent vinorelbine in pediatric patients with progressive optic pathway glioma.Journal of neuro-oncology · 2015Trial
- Pilocytic astrocytoma in pediatric and adult patients: a single-center analysis of 650 cases.Virchows Archiv : an international journal of pathology · 2026Article
- Unraveling the signaling mechanism behind astrocytoma and possible therapeutics strategies: A comprehensive review.Cancer reports (Hoboken, N.J.) · 2023Review
- Joint EANM/SIOPE/RAPNO practice guidelines/SNMMI procedure standards for imaging of paediatric gliomas using PET with radiolabelled amino acids and [European journal of nuclear medicine and molecular imaging · 2022Article
- Monomodality versus Combined Therapy in Optic Pathway Gliomas-20-Year Experience from a Singapore Children's Hospital.Frontiers in surgery · 2022Article
- Intraoperative squash Cytology of diffuse glioma not otherwise specified, of the Cerebellum.Acta bio-medica : Atenei Parmensis · 2021Article
- Conditional reprogramming culture conditions facilitate growth of lower-grade glioma models.Neuro-oncology · 2021Article
- Article
- NF-кB inhibition by DHMEQ: in vitro antiproliferative effects on pilocytic astrocytoma and concise review of the current literature.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2020Article
- Role of diffusion weighted imaging for differentiating cerebral pilocytic astrocytoma and ganglioglioma BRAF V600E-mutant from wild type.Neuroradiology · 2020Article
- Article
- Endothelium-Independent Primitive Myxoid Vascularization Creates Invertebrate-Like Channels to Maintain Blood Supply in Optic Gliomas.The American journal of pathology · 2017Article
- BRAF-V600E immunohistochemistry in a large series of glial and glial-neuronal tumors.Brain and behavior · 2017Article
- Zinc and zinc-containing biomolecules in childhood brain tumors.Journal of molecular medicine (Berlin, Germany) · 2016Review
- Postoperative surveillance of pediatric cerebellar pilocytic astrocytoma.Journal of neuro-oncology · 2016Article
- Future paradigms for precision oncology.Oncotarget · 2016Review
- Pediatric Brain Tumors: Current Knowledge and Therapeutic Opportunities.Journal of pediatric hematology/oncology · 2016Review
- Challenges in Drug Discovery for Neurofibromatosis Type 1-Associated Low-Grade Glioma.Frontiers in oncology · 2016Review
- Chromosome band 7q34 deletions resulting in KIAA1549-BRAF and FAM131B-BRAF fusions in pediatric low-grade Gliomas.Brain pathology (Zurich, Switzerland) · 2015Article
- The evolving molecular genetics of low-grade glioma.Advances in anatomic pathology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Pediatric low-grade astrocytomas are the most common brain tumors in children. They can have similar microscopic and clinical features, making accurate diagnosis difficult. For patients whose tumors are in locations that do not permit full resection, or those with an intrinsically aggressive biology, more effective therapies are required. Until recently, little was known about the molecular changes that drive the initiation and growth of pilocytic and other low-grade astrocytomas beyond the association of a minority of cases, primarily in the optic nerve, with neurofibromatosis type 1. Over the past several years, a wide range of studies have implicated the BRAF oncogene and other members of this signaling cascade in the pathobiology of pediatric low-grade astrocytoma. In this review, we attempt to summarize this rapidly developing field and discuss the potential for translating our growing molecular knowledge into improved diagnostic and prognostic biomarkers and new targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.